BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36089502)

  • 1. A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines.
    de Jong JJ; Pijpers OM; van Kessel KEM; Boormans JL; Van Criekinge W; Zwarthoff EC; Lotan Y
    Eur Urol Oncol; 2023 Apr; 6(2):183-189. PubMed ID: 36089502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
    Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
    Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Urine Based Genomic Assay to Triage Patients with Hematuria for Cystoscopy.
    van Kessel KEM; de Jong JJ; Ziel-van der Made ACJ; Roshani H; Haensel SM; Wolterbeek JH; Boevé ER; Oomens EHGM; van Casteren NJ; Krispin M; Boormans JL; Steyerberg EW; van Criekinge W; Zwarthoff EC
    J Urol; 2020 Jul; 204(1):50-57. PubMed ID: 31985322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a DNA Methylation-Mutation Urine Assay to Select Patients with Hematuria for Cystoscopy.
    van Kessel KE; Beukers W; Lurkin I; Ziel-van der Made A; van der Keur KA; Boormans JL; Dyrskjøt L; Márquez M; Ørntoft TF; Real FX; Segersten U; Malats N; Malmström PU; Van Criekinge W; Zwarthoff EC
    J Urol; 2017 Mar; 197(3 Pt 1):590-595. PubMed ID: 27746284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary Analysis of
    Lotan Y; Raman JD; Konety B; Daneshmand S; Schroeck F; Shariat SF; Black P; de Lange M; Asroff S; Goldfischer E; Efros M; Chong KT; Huang E; Chua HL; Wu QH; Yeow S; Lau W; Yong J; Eng M
    J Urol; 2023 Apr; 209(4):762-772. PubMed ID: 36583640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinoma.
    Kavalieris L; O'Sullivan PJ; Suttie JM; Pownall BK; Gilling PJ; Chemasle C; Darling DG
    BMC Urol; 2015 Mar; 15():23. PubMed ID: 25888331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective Blinded Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Carcinoma in Patients with Gross Hematuria.
    Dahmcke CM; Steven KE; Larsen LK; Poulsen AL; Abdul-Al A; Dahl C; Guldberg P
    Eur Urol; 2016 Dec; 70(6):916-919. PubMed ID: 27417036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of an Epigenetic Profile for the Detection of Bladder Cancer in Patients with Hematuria.
    van Kessel KE; Van Neste L; Lurkin I; Zwarthoff EC; Van Criekinge W
    J Urol; 2016 Mar; 195(3):601-7. PubMed ID: 26327355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
    Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
    BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of urothelial carcinoma, upper tract urothelial carcinoma, bladder carcinoma, and urothelial carcinoma with gross hematuria using selected urine-DNA methylation biomarkers: A prospective, single-center study.
    Guo RQ; Xiong GY; Yang KW; Zhang L; He SM; Gong YQ; He Q; Li XY; Wang ZC; Bao ZQ; Li XS; Zhang K; Zhou LQ
    Urol Oncol; 2018 Jul; 36(7):342.e15-342.e23. PubMed ID: 29706459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers.
    Bangma CH; Loeb S; Busstra M; Zhu X; El Bouazzaoui S; Refos J; Van Der Keur KA; Tjin S; Franken CG; van Leenders GJ; Zwarthoff EC; Roobol MJ
    Eur Urol; 2013 Jul; 64(1):41-7. PubMed ID: 23478169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective external validation of a bladder cancer detection model.
    Lotan Y; Svatek RS; Krabbe LM; Xylinas E; Klatte T; Shariat SF
    J Urol; 2014 Nov; 192(5):1343-8. PubMed ID: 24859442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BladMetrix: a novel urine DNA methylation test with high accuracy for detection of bladder cancer in hematuria patients.
    Pharo HD; Jeanmougin M; Ager-Wick E; Vedeld HM; Sørbø AK; Dahl C; Larsen LK; Honne H; Brandt-Winge S; Five MB; Monteiro-Reis S; Henrique R; Jeronimo C; Steven K; Wahlqvist R; Guldberg P; Lind GE
    Clin Epigenetics; 2022 Sep; 14(1):115. PubMed ID: 36115961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary-based tumor markers enhance microhematuria risk stratification according to baseline bladder cancer prevalence.
    Woldu SL; Souter L; Boorjian SA; Barocas DA; Lotan Y
    Urol Oncol; 2021 Nov; 39(11):787.e1-787.e7. PubMed ID: 33858747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer.
    Fantony JJ; Abern MR; Gopalakrishna A; Owusu R; Jack Tay K; Lance RS; Inman BA
    Urol Oncol; 2015 Sep; 33(9):387.e1-6. PubMed ID: 26027762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical performance and utility of a noninvasive urine-based methylation biomarker: TWIST1/Vimentin to detect urothelial carcinoma of the bladder.
    Zhang C; Xu X; Wang T; Lu Y; Lu Z; Wang T; Pan Z
    Sci Rep; 2024 Apr; 14(1):7941. PubMed ID: 38575639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness of a multitarget urine DNA test for urothelial carcinoma detection: a double-blinded, multicenter, prospective trial.
    Wu J; Lin Y; Yang K; Liu X; Wang H; Yu T; Tao R; Guo J; Chen L; Cheng H; Lou F; Cao S; Yu W; Hu H; Ye D
    Mol Cancer; 2024 Mar; 23(1):57. PubMed ID: 38504268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary NID2 and TWIST1 methylation to augment conventional urine cytology for the detection of bladder cancer.
    Fantony JJ; Longo TA; Gopalakrishna A; Owusu R; Lance RS; Foo WC; Inman BA; Abern MR
    Cancer Biomark; 2017; 18(4):381-387. PubMed ID: 28106542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.
    Woldu SL; Ng CK; Loo RK; Slezak JM; Jacobsen SJ; Tan WS; Kelly JD; Lough T; Darling D; van Kessel KEM; de Jong JJ; van Criekinge W; Shariat SF; Hiar A; Brown S; Boorjian SA; Barocas DA; Svatek RS; Lotan Y
    J Urol; 2021 May; 205(5):1387-1393. PubMed ID: 33356483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas.
    Kodama H; Yoneyama T; Tanaka T; Noro D; Tobisawa Y; Yamamoto H; Suto S; Hatakeyama S; Mori K; Yoneyama T; Hashimoto Y; Kakizaki I; Nakaji S; Ohyama C
    Cancer Med; 2021 Feb; 10(4):1297-1313. PubMed ID: 33455069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.